> I thought it was only approved for diabetes not obesity.
Ozempic and Wegovy are the same substance from the same company, Ozempic is approved for diabetes, Wegovy is approved for obesity. Similar situations apply to other competing GLP1 agonists.
oh yea i think i have some family on wegovy ( or maybe mounjaro now ), hadn't realized that it was approved for obesity.
What i don't understand is that you are saying these are "preventative treatments for obesity" . aren't preventative treatements given before the condition even comes into picture, these drugs are after you get obese so not sure how they are preventative.
Doesn't weight just come back instantly once you stop these drugs. Hard time accepting that solution is putting 200million americans on this drug for rest of their lives.
"Cardiometabolic improvements seen from week 0 to week 68 with semaglutide reverted towards baseline at week 120 for most variables."
I didn't say it prevents obesity, I said it prevents Type 2 Diabetes, which is a chronic disease caused by obesity. And it does. It's nearly a miracle drug.
Yes, if you stop taking the drugs, after a short time you return exactly how you were prior. You must take these drugs for life, unless something else comes out that improves the situation.
Ah I understand now what you meant. I remember looking into while ago( i have like half my extended family on these drugs now lol) but couldn't really find evidence to support this claim.
"There is only limited-quality evidence that at-risk patients taking GLP-1 receptor agonists are less likely to progress to diabetes (number needed to treat [NNT] = 23). Serious adverse events were more likely in patients taking GLP-1 receptor agonists than in patients taking placebo (number needed to harm [NNH] = 42). There is insufficient evidence to evaluate the effect of DPP-4 inhibitors on at-risk patients. There is no evidence that either medication class affects the development of diabetes-associated complications.1"
My impression was that obese people first get less insulin sensitive over the years and then become obese as a result.
They usually measure insulin sensitivity as a proxy to 'metabolism'.
> It should be affordable and accessible for nearly anyone in the US to get access to GLP1 agonists and a dietitian.
I thought it was only approved for diabetes not obesity.